Second malignancies in patients with Ewing Sarcoma Family of Tumors: A population-based study

References

• Dorfman HD, Czerniak B. Bone cancers. Cancer 1995; 75:203–10.
   PubMed Web of Science ®Google Scholar
• Esiashvili N, Goodman M, Marcus RB, Jr. Changes in incidence and survival of Ewing Sarcoma patients over the past 3 decades: Surveillance epidemiology and end results data. J Pediatr Hematol Oncol 2008; 30:425–30.
   PubMed Web of Science ®Google Scholar
• Navid F, Billups C, Liu T, Krasin MJ, Rodriguez-Galindo C. Second cancers in patients with the Ewing Sarcoma Family of Tumours. Eur J Cancer 2008; 44:983–91.
   PubMed Web of Science ®Google Scholar
• Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, . Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's Sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348:694–701.
   PubMed Web of Science ®Google Scholar
• Inskip PD, Curtis RE. New malignancies following childhood cancer in the United States, 1973-2002. Int J Cancer 2007; 121:2233–40.
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology and End Results (SEER) Program(www.seer.cancer.gov)SEER*Stat Database: Incidence - SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2007 Sub (1973–2005 varying) - Linked To County Attributes - Total U.S., 1969–2005 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008, based on the November 2007 submission.
   Google Scholar
• Wingo PA, Jamison PM, Hiatt RA, Weir HK, Gargiullo PM, Hutton M, Lee NC, Hall HI: Building the infrastructure for nationwide cancer surveillance and control–a comparison between the national program of cancer registries (npcr) and the surveillance, epidemiology, and end results (seer) program (united states). Cancer Causes Control 2003;14:175–93.
   PubMed Web of Science ®Google Scholar
• Yu JB, Gross CP, Wilson LD, Smith BD. NCI seer public-use data: Applications and limitations in oncology research. Oncology (Williston Park) 2009; 23:288–95.
   PubMed Web of Science ®Google Scholar
• Surveillance research program, national cancer institute seer*stat software (www.Seer.Cancer.Gov/seerstat) version 6.4.4.
   Google Scholar
• Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International classification of childhood cancer, 3rd. Cancer 2005; 103:1457–67.
   PubMed Web of Science ®Google Scholar
• Aparicio J, Segura A, Montalar J, Verdeguer A, Castel V, Sanchez-Heras AB. “Secondary cancers after Ewing Sarcoma and Ewing Sarcoma as second malignant neoplasm”. Med Pediatr Oncol 1998; 30:259–60.
   PubMedGoogle Scholar
• Bacci G, Longhi A, Barbieri E, Ferrari S, Mercuri M, Briccoli A, . Second malignancy in 597 patients with Ewing Sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. J Pediatr Hematol Oncol 2005; 27:517–20.
   PubMedGoogle Scholar
• Dunst J, Ahrens S, Paulussen M, Rube C, Winkelmann W, Zoubek A, . Second malignancies after treatment for Ewing's Sarcoma: A report of the cess-studies. Int J Radiat Oncol Biol Phys 1998; 42:379–84.
   PubMed Web of Science ®Google Scholar
• Gasparini M, Lombardi F, Ballerini E, Gandola L, Gianni MC, Massimino M, . Long-term outcome of patients with monostotic Ewing's Sarcoma treated with combined modality. Med Pediatr Oncol 1994; 23:406–12.
   PubMedGoogle Scholar
• Kuttesch JF, Jr., Wexler LH, Marcus RB, Fairclough D, Weaver-McClure L, White M, . Second malignancies after Ewing's Sarcoma: Radiation dose-dependency of secondary sarcomas. J Clin Oncol 1996; 14:2818–25.
   PubMed Web of Science ®Google Scholar
• McLean TW, Hertel C, Young ML, Marcus K, Schizer MA, Gebhardt M, . Late events in pediatric patients with Ewing Sarcoma /primitive neuroectodermal tumor of bone: The dana-farber cancer institute/children's hospital experience. J Pediatr Hematol Oncol 1999; 21:486–93.
   PubMed Web of Science ®Google Scholar
• Paulussen M, Ahrens S, Lehnert M, Taeger D, Hense HW, Wagner A, . Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. Ann Oncol 2001; 12:1619–30.
   PubMed Web of Science ®Google Scholar
• Smith LM, Cox RS, Donaldson SS. Second cancers in long-term survivors of Ewing's Sarcoma. Clin Orthop Relat Res 1992; :275–81.
   PubMedGoogle Scholar
• Travis LB, Curtis RE, Hankey BF, Fraumeni JF, Jr. Second cancers in patients with Ewing's Sarcoma. Med Pediatr Oncol 1994; 22:296–7.
   PubMedGoogle Scholar
• Strong LC, Herson J, Osborne BM, Sutow WW. Risk of radiation-related subsequent malignant tumors in survivors of Ewing's Sarcoma. J Natl Cancer Inst 1979; 62:1401–6.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Krailo MD, Chen Z, Burden L, Askin FB, Dickman PS, . Therapy-related myelodysplasia and acute myeloid leukemia after Ewing Sarcoma and primitive neuroectodermal tumor of bone: A report from the children's oncology group. Blood 2007; 109:46–51.
   PubMed Web of Science ®Google Scholar
• Relling MV, Boyett JM, Blanco JG, Raimondi S, Behm FG, Sandlund JT, . Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003; 101:3862–7.
   PubMed Web of Science ®Google Scholar
• Collins MK, Marvel J, Malde P, Lopez-Rivas A. Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents. J Exp Med 1992; 176:1043–51.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Galindo C, Poquette CA, Marina NM, Head DR, Cain A, Meyer WH, . Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing Sarcoma Family of Tumors. J Pediatr Hematol Oncol 2000; 22:321–9.
   PubMed Web of Science ®Google Scholar
• van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, Hagenbeek A, Noyon R, van Kerkhoff EH, . Leukemia risk following Hodgkin's disease: Relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 1994; 12:1063–73.
   PubMed Web of Science ®Google Scholar
• Morley A, Trainor K, Blake J. A primary stem cell lesion in experimental chronic hypoplastic marrow failure. Blood 1975; 45:681–8.
   PubMedGoogle Scholar
• Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: Incidence and survival in the United States. Cancer 2007; 109:1536–42.
   PubMed Web of Science ®Google Scholar
• Henderson TO, Whitton J, Stovall M, Mertens AC, Mitby P, Friedman D, . Secondary sarcomas in childhood cancer survivors: A report from the childhood cancer survivor study. J Natl Cancer Inst 2007; 99:300–8.
   PubMedGoogle Scholar
• Tucker MA, D'Angio GJ, Boice JD Jr., Strong LC, Li FP, Stovall M, . Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987; 317:588–93.
   PubMed Web of Science ®Google Scholar
• Womer RB, Daller RT, Fenton JG, Miser JS. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's Sarcomas and soft tissue sarcomas in children. Eur J Cancer 2000; 36:87–94.
   PubMed Web of Science ®Google Scholar